4 Firms Lead Canadian Biotech Aurinia's $173M Follow-On
Canadian biotech Aurinia Pharmaceuticals Inc. said Monday it closed a $173 million follow-on offering to help fund its top drug candidate treating lupus, a deal guided by four law firms....To view the full article, register now.
Already a subscriber? Click here to view full article